We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 18.00 | 17.50 | 18.50 | 18.00 | 18.00 | 18.00 | 53,830 | 07:48:33 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.34 | 16.41M |
Date | Subject | Author | Discuss |
---|---|---|---|
30/4/2024 10:31 | It needs ro be a separate report, and not just "10 million "de_risked cash extraction expenses" 😂 Every £1 accounted for in detail, not just a category Give them something to do anyway before next holiday Investors deserve this detailed report. Its not a tall order. Its an expectation . | institutional investments | |
30/4/2024 10:28 | Expecting a detailed breakdown of sbtx sells in £ total, less costs, and what cash is left at bank from it. A further detailed breakdown of cash not at bank from the sells as well Market needs this and I see no reason not to give it .. We need to see in detail, what the "de_riskimg' produced nett for opti investors Well, maybe one or two reasons | institutional investments | |
30/4/2024 10:25 | Plus a raise | institutional investments | |
30/4/2024 07:32 | ‘ creating a local manufacturing and sales base for ingredient and finished product’ Oh another one of those? So overseas sales, minus overseas cost of sales, equals vast recognised revenues, and next to no cash ? | kreature | |
30/4/2024 07:29 | ‘KAG… ‘ supply of Slimbiome® containing products ready for sale’ So what is in it ? ‘ containing products ready for sale ‘ What products ? | kreature | |
30/4/2024 07:20 | Another RNS Stretch. So could be a quid today with a podcast perhaps ? Depends if the maker is independent I guess ? Sorry, silly question lol | kreature | |
30/4/2024 07:09 | Great. More manufacturing agreements. No sales as per decade | institutional investments | |
29/4/2024 14:24 | Another lovely day i mean the weather, obviously | institutional investments | |
28/4/2024 21:57 | The fees for trying ? Consultancy fees ? Commission ? I dunno | kreature | |
28/4/2024 21:44 | Non operational expenses circa 10 million. Whats tha? The fees for doing nothing? | institutional investments | |
21/4/2024 20:30 | Could also highlight in a lecture how any brand can be globally derisked for a bit by selling Sbtx shares | kreature | |
21/4/2024 20:24 | Credibility could be secured with another YouTube interview/lecture on brand unawareness | kreature | |
21/4/2024 12:18 | umm ok it's me pushing it to far fetched now re credibility purposes lol | institutional investments | |
21/4/2024 12:17 | But you know, jees, maybe try it in April or June this year, just for credibility purposes | institutional investments | |
21/4/2024 12:16 | I do not know if you can get away with it 3 years in a row? But a July 2024 like July 2023 and July 2022 for distribution re summer holiday financing purposes, may be going too far, re 3 years in a row# i get it like. it is best month to catch retail before all disappear in school holiday period. | institutional investments | |
21/4/2024 12:13 | i would rather see them make up for this week,any ol thing for the maker to work with tbf | institutional investments | |
21/4/2024 12:12 | this needs news tomorrow. Im sure the maker has no choice but to sink it without news, so just have to hope they give him some. Timing suggests it is required now, unless being allowed to hit 5p again | institutional investments | |
21/4/2024 11:22 | Hopefully the broker has no conflict of interests, along with the auditor, and they are going above and beyond to verify all, to ensure opti is not getting scammed | institutional investments |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions